SMS Pharmaceuticals expands equity base after warrant conversions

SMS Pharmaceuticals Limited's Securities Allotment Committee approved the allotment of 5m equity shares on September 10, 2025. This action resulted from the conversion of 5m warrants, following the receipt of the balance amount aggregating to INR 4,762,500,000. Each warrant was converted at an effective rate of INR 95.25, representing 75% of the issue price.

These newly allotted equity shares will rank pari-passu with existing shares. Consequently, the company's paid-up share capital has risen from INR 8,865,20,30 to INR 9,365,20,30, reflecting the increase to 9,36,52,030 equity shares of INR 1 each. This allotment completes the conversion of all previously issued warrants.

The process aligns with the company's prior announcements on March 19, 2024, and March 27, 2025, and adheres to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The conversion involved two warrant holders, Mr. Vamsi Krishna Potluri and Mr. Trilok Potluri, each converting 2,500,000 warrants into an equal number of equity shares.